PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for August 5, 2008 Subscribe to this News Feed    
 

Akaza Research Announces Plans for Releasing New Version of OpenClinica Electronic Data Capture (EDC) Software

Akaza Research announces the forthcoming release version 2.5 of OpenClinica, the popular open source clinical trial software.

Cambridge, MA (PRWEB) August 5, 2008 -- This summer Akaza Research expects to release version 2.5 of OpenClinica, the popular open source clinical trial software. This release represents a major milestone in the availability of enterprise quality open source software for electronic data capture (EDC) and clinical data management. The release contains improvements to both the system's back and front-ends, and promises to further increase the appeal of OpenClinica to academic, CRO, and industry research sponsors:

Key enhancements in OpenClinica 2.5 include:
-   Rules engine for executing cross-field or cross-form edit checks and triggering notifications to users
-   Scoring calculations (derived values) in case report forms (CRFs)
-   New user roles for monitors and data managers
-   Improved monitoring/query management tools and discrepancy note reporting
-   Electronic signature capabilities
-   Ability to copy and edit previously created datasets
-   Improved auditing and logging capabilities
-   Simpler CRF upload
-   Improved support for CDISC ODM v1.3
-   Support for Oracle DB Backend out of the box.
-   Minor UI and application fixes from OpenClinica 2.2
-   Improved performance and scalability

Until the production version is available, users may download OpenClinica 2.5-beta2 from http://svn.akazaresearch.com/OpenClinica-2.5-distros/. OpenClinica 2.5 will maintain backwards compatibility with earlier versions of the software. An upgrade package will be provided with the production release.

About OpenClinica®
OpenClinica is open source web-based electronic data capture software for clinical research. It facilitates protocol configuration, design of case report forms, clinical data capture, and study/data management. OpenClinica supports HIPAA and 21 CFR Part 11 guidelines and is designed as a lightweight, standards-based, extensible, and modular platform. All versions of OpenClinica are available for download at www.OpenClinica.org.

About Akaza Research®
Akaza Research, the leading provider of open source clinical trial software, is headquartered in Cambridge, Massachusetts. Supported by the National Institutes of Health (NIH), Akaza has developed and commercialized OpenClinica, the preeminent open source clinical trial data capture and management software platform. Akaza brings Open Source Software (OSS) into the mainstream of the clinical research enterprise by making robust, flexible, standards-based systems accessible for all types of clinical research. Akaza Research provides OpenClinica support, training, and consulting services to its customers worldwide. See www.akazaresearch.com.
###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1JbnNlLVByb2YtRmFsdS1TaW5nLVNpbmctWmVybw==

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
Ben Baumann
Akaza Research
617-621-8585
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Close Move